These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 19531256)
1. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Rene Gonzalez R; Watters A; Xu Y; Singh UP; Mann DR; Rueda BR; Penichet ML Breast Cancer Res; 2009; 11(3):R36. PubMed ID: 19531256 [TBL] [Abstract][Full Text] [Related]
2. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). Gonzalez RR; Cherfils S; Escobar M; Yoo JH; Carino C; Styer AK; Sullivan BT; Sakamoto H; Olawaiye A; Serikawa T; Lynch MP; Rueda BR J Biol Chem; 2006 Sep; 281(36):26320-8. PubMed ID: 16825198 [TBL] [Abstract][Full Text] [Related]
3. Obesity induced a leptin-Notch signaling axis in breast cancer. Battle M; Gillespie C; Quarshie A; Lanier V; Harmon T; Wilson K; Torroella-Kouri M; Gonzalez-Perez RR Int J Cancer; 2014 Apr; 134(7):1605-16. PubMed ID: 24114531 [TBL] [Abstract][Full Text] [Related]
4. Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling. Zhou W; Guo S; Gonzalez-Perez RR Br J Cancer; 2011 Jan; 104(1):128-37. PubMed ID: 21139583 [TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-linked antagonist for leptin signaling inhibition in breast cancer. Harmon T; Harbuzariu A; Lanier V; Lipsey CC; Kirlin W; Yang L; Gonzalez-Perez RR World J Clin Oncol; 2017 Feb; 8(1):54-66. PubMed ID: 28246585 [TBL] [Abstract][Full Text] [Related]
6. Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Ray A; Nkhata KJ; Cleary MP Int J Oncol; 2007 Jun; 30(6):1499-509. PubMed ID: 17487372 [TBL] [Abstract][Full Text] [Related]
7. The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor. Sarwar M; Syed Khaja AS; Aleskandarany M; Karlsson R; Althobiti M; Ødum N; Mongan NP; Dizeyi N; Johnson H; Green AR; Ellis IO; Rakha EA; Persson JL Oncogene; 2019 Jan; 38(3):375-389. PubMed ID: 30104711 [TBL] [Abstract][Full Text] [Related]
8. Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway. Haque I; Ghosh A; Acup S; Banerjee S; Dhar K; Ray A; Sarkar S; Kambhampati S; Banerjee SK BMC Cancer; 2018 Jan; 18(1):99. PubMed ID: 29370782 [TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression. Applanat MP; Buteau-Lozano H; Herve MA; Corpet A Adv Exp Med Biol; 2008; 617():437-44. PubMed ID: 18497067 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112 [TBL] [Abstract][Full Text] [Related]
11. Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells. Jiang C; Guo J; Wang Z; Xiao B; Lee HJ; Lee EO; Kim SH; Lu J Breast Cancer Res; 2007; 9(6):R77. PubMed ID: 17986353 [TBL] [Abstract][Full Text] [Related]
12. Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. Minoia M; Gentilin E; Molè D; Rossi M; Filieri C; Tagliati F; Baroni A; Ambrosio MR; degli Uberti E; Zatelli MC J Clin Endocrinol Metab; 2012 Jun; 97(6):E907-16. PubMed ID: 22442272 [TBL] [Abstract][Full Text] [Related]
13. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft. Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847 [TBL] [Abstract][Full Text] [Related]
14. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. Zou Y; Tsai WB; Cheng CJ; Hsu C; Chung YM; Li PC; Lin SH; Hu MC Breast Cancer Res; 2008; 10(1):R21. PubMed ID: 18312651 [TBL] [Abstract][Full Text] [Related]
15. Role of adipokines and cytokines in obesity-associated breast cancer: therapeutic targets. Khan S; Shukla S; Sinha S; Meeran SM Cytokine Growth Factor Rev; 2013 Dec; 24(6):503-13. PubMed ID: 24210902 [TBL] [Abstract][Full Text] [Related]
16. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682 [TBL] [Abstract][Full Text] [Related]
17. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749 [TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association. Tonsing-Carter E; Hernandez KM; Kim CR; Harkless RV; Oh A; Bowie KR; West-Szymanski DC; Betancourt-Ponce MA; Green BD; Lastra RR; Fleming GF; Chandarlapaty S; Conzen SD Breast Cancer Res; 2019 Jul; 21(1):82. PubMed ID: 31340854 [TBL] [Abstract][Full Text] [Related]
19. Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway. Thoennissen NH; O'Kelly J; Lu D; Iwanski GB; La DT; Abbassi S; Leiter A; Karlan B; Mehta R; Koeffler HP Oncogene; 2010 Jan; 29(2):285-96. PubMed ID: 19855437 [TBL] [Abstract][Full Text] [Related]